BioRestorative Therapies Reports Q2 Results
Ticker: BRTX · Form: 8-K · Filed: Aug 13, 2024 · CIK: 1505497
Sentiment: neutral
Topics: financial-results, 8-k, reporting
TL;DR
BRTX dropped Q2 earnings report, check financials.
AI Summary
BioRestorative Therapies, Inc. filed an 8-K on August 13, 2024, to report its financial results for the second quarter. The filing details the company's operational and financial condition, including financial statements and exhibits. The report covers the period ending August 13, 2024.
Why It Matters
This filing provides investors with the latest financial performance data for BioRestorative Therapies, Inc., crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial reporting event with no immediate significant changes or events indicated.
Key Players & Entities
- BioRestorative Therapies, Inc. (company) — Registrant
- August 13, 2024 (date) — Date of Report
- Nevada (jurisdiction) — State of incorporation
- 40 Marcus Drive Melville, New York 11747 (address) — Principal executive offices
- Stem Cell Assurance, Inc. (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report the Results of Operations and Financial Condition of BioRestorative Therapies, Inc., along with Regulation FD Disclosure and Financial Statements and Exhibits for the period ending August 13, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 13, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 40 Marcus Drive, Melville, New York 11747.
What was the former name of BioRestorative Therapies, Inc.?
The former name of BioRestorative Therapies, Inc. was Stem Cell Assurance, Inc., with a date of name change on November 10, 2010.
What is the company's IRS Employer Identification Number?
The company's IRS Employer Identification Number is 30-1341024.
Filing Stats: 721 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2024-08-13 16:11:03
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value BRTX NASDAQ Capital Marke
Filing Documents
- brt81324.htm (8-K) — 26KB
- ex99_1.htm (EX-99.1) — 2KB
- brtpr_1.jpg (GRAPHIC) — 867KB
- brtpr_2.jpg (GRAPHIC) — 840KB
- brtpr_3.jpg (GRAPHIC) — 1145KB
- brtpr_4.jpg (GRAPHIC) — 222KB
- 0001021771-24-000166.txt ( ) — 4393KB
- brtx-20240813.xsd (EX-101.SCH) — 4KB
- brtx-20240813_lab.xml (EX-101.LAB) — 22KB
- brtx-20240813_pre.xml (EX-101.PRE) — 16KB
- brt81324_htm.xml (XML) — 4KB
02
Item 2.02. Result of Operations and Financial Condition. On August 13, 2024, BioRestorative Therapies, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2024 (the "Press Release"). The Press Release also provided a business update and included details with regard to the conference call to be held to discuss the second quarter results. A copy of the Press Release is furnished as Exhibit 99.1 hereto. The information contained in the Press Release is summary information that should be considered in the context of the Company's filings with the Securities and Exchange Commission and other public announcements that the Company may make by press release or otherwise from time to time. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01
Item 7.01 Regulation FD Disclosure . See Item 2.02 above. The information in the Press Release is being furnished, not filed, pursuant to this Item 7.01. Accordingly, the information in the Press Release will not be incorporated by reference into any registration statement filed by the Company under the Securities Act unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this Current Report on Form 8-K with respect to the Press Release is not intended to, and does not, constitute a determination or admission by the Company that the information in this Current Report on Form 8-K with respect to the Press Release is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.
Financial Statements and Exhibits
Financial Statements and Exhibits . (d) Exhibits . Number Description 99.1 Press release, dated August 13, 2024, issued by BioRestorative Therapies, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIORESTORATIVE THERAPIES, INC. Dated: August 13, 2024 By: /s/ Robert Kristal Robert Kristal Chief Financial Officer